Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Safety and Immunogenicity of GSK Biological’s Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-Negative Adults.
This study has been completed.
Sponsored by: GlaxoSmithKline
Information provided by: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00291889
  Purpose

Vaccination against tuberculosis (TB) /healthy PPD-negative adults aged 18 to 45 years.Three doses of primary vaccination followed by a booster dose after completion of primary vaccination course. Booster vaccination will be given only to subjects receiving the candidate tuberculosis vaccines and not to the subjects receiving active comparators or control.


Condition Intervention Phase
Tuberculosis
Biological: Mtb72F/AS02.
Phase I
Phase II

MedlinePlus related topics: Tuberculosis
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety Study
Official Title: Evaluate the Safety, Reactogenicity & Immunogenicity of 2 Antigen Dose Levels of GSK Biologicals’ Candidate Tuberculosis Vaccine, Mtb72F/AS02 to Healthy PPD-Negative Volunteers Aged 18 to 45 Yrs

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Occurrence of solicited symptoms during the 7-day follow-up period, unsolicited symptoms during the 30-day follow-up period, grade 3 vaccine related local and general symptoms during the 30-day follow-up and serious adverse events during the entire study

Secondary Outcome Measures:
  • Immunogenicity as assessed by humoral and CMI response.

Estimated Enrollment: 50
Study Start Date: July 2004
Detailed Description:

The safety and immunogenicity of 2 antigen doses in PPD-negative adults will be evaluated. In addition, 2 active comparator groups of volunteers will receive the vaccine alone without an immunostimulant and 1 control group will receive the adjuvant (AS02) alone to assess the true effect of the candidate tuberculosis vaccine (Mtb72F/AS02).

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

INCLUSION CRITERIA:

  • Written informed consent
  • Healthy PPD-negative volunteers aged 18 to 45 years
  • No evidence of pulmonary pathology (i.e. acute or chronic pulmonary disease; past TB infection/disease) as confirmed by chest X-ray.
  • Seronegative for HIV 1 and 2, HBsAg, and HCV
  • Clinically normal laboratory values for creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, complete blood count (CBC) and differential, haemoglobin, platelet count and urinalysis.
  • Females : Non pregnant, must use adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series.

EXCLUSION CRITERIA:

  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose.
  • History of prior Bacillus Calmette-Guérin (BCG) vaccination.
  • History of documented exposure to Mycobacterium tuberculosis
  • History of prior vaccination with experimental Mycobacterium Tuberculosis vaccines or experimental products containing MPL or QS21.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition; or family history of congenital or hereditary immunodeficiency.
  • History of hypersensitivity to vaccines or vaccine components
  • History of any acute or chronic illness or medication that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine"
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00291889

Locations
Belgium
Ghent, Belgium
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: Clinical Trials GlaxoSmithKline
  More Information

Study ID Numbers: 102039
Study First Received: February 14, 2006
Last Updated: February 6, 2007
ClinicalTrials.gov Identifier: NCT00291889  
Health Authority: Belgium: Ministry of Social Affairs, Public Health and the Environment

Study placed in the following topic categories:
Bacterial Infections
Gram-Positive Bacterial Infections
Mycobacterium Infections
Tuberculosis
Healthy

Additional relevant MeSH terms:
Actinomycetales Infections

ClinicalTrials.gov processed this record on January 16, 2009